CR 2991

Drug Profile

CR 2991

Latest Information Update: 24 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rottapharm
  • Class Antihypertensives
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Benign prostatic hyperplasia; Essential hypertension

Most Recent Events

  • 17 Jun 2005 CR 2991 is available for licensing (
  • 07 Mar 2005 Preclinical trials in Benign prostatic hyperplasia in Italy (unspecified route)
  • 16 May 2003 Preclinical trials in Essential hypertension in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top